QUÉBEC CITY, June 14
/PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX:
AEZ), (the "Company") a late-stage drug development company
specialized in oncology and endocrine therapy, today announced that
a poster on its oral synthetic growth hormone secretagogue/ghrelin
receptor agonist, AEZS-130, will be presented at the upcoming 92nd
Annual Endocrine Society (ENDO) Meeting and Expo, which will be
held June 19 through 22, 2010 at the
San Diego Convention Center in
San Diego, California. AEZS-130
(Solorel(TM)) is currently in a Phase 3 trial as a diagnostic test
for growth hormone deficiency in adults.
Abstract #851112: "Pharmacological and Toxicological Evaluation of
AEZS-130, a Novel, Oral Synthetic Growth Hormone
Secretagogue//Ghrelin Receptor Agonist for the
Diagnosis of Growth Hormone Deficiency", Babette
Aicher, Peter Schmidt, Elena Bresciani, Vittorio
Locatelli, Daniel Perrissoud, Michael Teifel
Presenter: Dr. Babette Aicher, Associate Director - Screening
& Profiling, Preclinical Development, Aeterna
Zentaris
Date and Time: Sunday, June 20, 2010, 1:30 pm - 3:30 pm
(local time)
Poster Board #: P2-340
Location: Halls D-G, San Diego Convention Center
A copy of this abstract is currently available on the ENDO
website at www.endo-society.org.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a late-stage drug development company
specialized in oncology and endocrine therapy. News releases and
additional information are available at www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.